Literature DB >> 15334452

Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus.

Joel Schiffenbauer1, Bevra Hahn, Michael H Weisman, Lee S Simon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15334452     DOI： 10.1002/art.20353

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  10 in total

Review 1.  [Glucocorticoid therapy in collagen diseases diseases].

Authors:  L Unger; M Kayser; M Enderlein; K Manger; H Nüsslein
Journal:  Z Rheumatol       Date:  2005-04       Impact factor: 1.372

2.  Biomarkers of lupus nephritis determined by serial urine proteomics.

Authors:  Xiaolan Zhang; Ming Jin; Haifeng Wu; Tibor Nadasdy; Gyongyi Nadasdy; Nathan Harris; Kari Green-Church; Haikady Nagaraja; Daniel J Birmingham; Chack-Yung Yu; Lee A Hebert; Brad H Rovin
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

3.  Identification of interferon-inducible genes as diagnostic biomarker for systemic lupus erythematosus.

Authors:  Xuebing Feng; Jing Huang; Yan Liu; Lihui Xiao; Dandan Wang; Bingzhu Hua; Betty P Tsao; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2014-10-26       Impact factor: 2.980

4.  Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4.

Authors:  Heikki Julkunen; Susanne Ekblom-Kullberg; Aaro Miettinen
Journal:  Rheumatol Int       Date:  2011-06-26       Impact factor: 2.631

5.  Detection of dynamic frequencies of Th17 cells and their associations with clinical parameters in patients with systemic lupus erythematosus receiving standard therapy.

Authors:  Zhenke Wen; Lin Xu; Wei Xu; Sidong Xiong
Journal:  Clin Rheumatol       Date:  2014-05-10       Impact factor: 2.980

6.  Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis.

Authors:  Michiko Suzuki; Kristina M Wiers; Marisa S Klein-Gitelman; Kathleen A Haines; Judyann Olson; Karen B Onel; Kathleen O'Neil; Murray H Passo; Nora G Singer; Lori Tucker; Jun Ying; Prasad Devarajan; Hermine I Brunner
Journal:  Pediatr Nephrol       Date:  2008-01-17       Impact factor: 3.714

Review 7.  Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects.

Authors:  Fanny Monneaux; Sylviane Muller
Journal:  Arthritis Res Ther       Date:  2009-06-30       Impact factor: 5.156

8.  Identification of a urinary proteomic signature for lupus nephritis in children.

Authors:  Michiko Suzuki; Gary F Ross; Kristina Wiers; Shannen Nelson; Michael Bennett; Murray H Passo; Prasad Devarajan; Hermine I Brunner
Journal:  Pediatr Nephrol       Date:  2007-09-28       Impact factor: 3.714

9.  Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.

Authors:  Jason W Bauer; Michelle Petri; Franak M Batliwalla; Thearith Koeuth; Joseph Wilson; Catherine Slattery; Angela Panoskaltsis-Mortari; Peter K Gregersen; Timothy W Behrens; Emily C Baechler
Journal:  Arthritis Rheum       Date:  2009-10

10.  Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses.

Authors:  Bo Chen; Katherine A Vousden; Brian Naiman; Sean Turman; Hong Sun; Shu Wang; Lisa M K Vinall; Benjamin P Kemp; Srinath Kasturiangan; D Gareth Rees; Ethan Grant; Mary Jane Hinrichs; Steven Eck; Antonio DiGiandomenico; M Jack Borrok; Neang Ly; Ximing Xiong; Carlos Gonzalez; Christopher Morehouse; Yue Wang; Yebin Zhou; Jennifer Cann; Weiguang Zhao; Holly Koelkebeck; Koshu Okubo; Tanya N Mayadas; David Howe; Janet Griffiths; Roland Kolbeck; Ronald Herbst; Gary P Sims
Journal:  Ann Rheum Dis       Date:  2018-11-20       Impact factor: 19.103
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.